Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease

Area of Science:

• Neonatology
• Pediatric Gastroenterology
• Nutritional Science

Background:

• Parenteral nutrition-associated liver disease (PNALD) is a serious complication in infants receiving long-term intravenous nutrition.
• The role of intravenous lipid emulsion in PNALD pathogenesis is suspected but not fully elucidated.

Purpose of the Study:

• To investigate whether a significant reduction in intravenous fat administration can reverse PNALD in infants.
• To assess the safety and efficacy of a modified lipid regimen for PNALD treatment.

Main Methods:

• A prospective study involving neonates diagnosed with PNALD.
• Reduced intravenous fat emulsion to 1 g/kg/d, 2 times per week, compared to historical controls receiving 3 g/kg/d.
• Primary outcome was total bilirubin levels; growth and essential fatty acid status were monitored.

Main Results:

• Intravenous fat reduction led to a significant decrease in total bilirubin levels compared to controls.
• Infant growth was comparable between the reduced-fat and control groups.
• Mild essential fatty acid deficiency occurred in some infants but was reversible; no significant adverse events were observed.

Conclusions:

• A strong association between high-dose intravenous lipid emulsion and PNALD development is likely.
• Reducing intravenous fat is a viable strategy for reversing PNALD in infants.
• Close monitoring for essential fatty acid deficiency is crucial when implementing this regimen.